IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3103
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$617M
Matthew Pauls
Savara Inc. focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor. The company is headquartered in Austin, Texas.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$SVRA Savara Inc | 43 | 22 | 36 | 80 | - | - | -78.7% | -78.7% | - | - | - | - | 0.0% | 32.0x | $617M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Savara Inc (SVRA) receives a "Reduce" rating with a composite score of 43.1/100. It ranks #3103 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SVRA.
View All RatingsROIC -177.0% vs WACC 9.6% (spread -186.6%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover 0.00x
Rev growth N/A, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Savara Inc (SVRA) as a Reduce with a composite score of 43.1/100 at a current price of $5.64. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Savara Inc holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.1/100 places it at rank #3103 in our full universe.
No Moat
Low
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Savara Inc represents a reduce based on multi-factor quantitative performance.
Savara Inc receives a Reduce rating from our analysis, with a composite score of 43.1/100 and 2 out of 5 stars, ranking #3103 out of 7,333 stocks. SVRA's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Savara Inc registers a weak quality score of just 22/100, indicating significant profitability challenges. The company reports a return on equity of -78.7% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 36/100, SVRA appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 6.54x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Savara Inc's investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -78.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SVRA shows strong momentum characteristics with a score of 80/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of 0.65 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 58/100, SVRA exhibits average financial resilience. Key stability metrics include a beta of 0.65 and a debt-to-equity ratio of 32.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Savara Inc's short interest score of 31/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 32.00x), small-cap liquidity risk. At $617M (small-cap), SVRA carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Savara Inc is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3103 of 7,333 overall (58th percentile). Key comparisons include ROE of -78.7% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SVRA currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (22) would have the largest impact on the composite score.
ROE 4044% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 15138% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Citizens reiterated a Market Outperform rating and a $10.00 price target for Savara (NASDAQ:SVRA), citing a 90% probability of FDA approval for its drug Molbreevi, which treats aPAP. The firm views the Priority Review status as a strong indicator of the FDA's recognition of the unmet need. Savara's stock has seen a 106% return over the past year, reflecting market optimism, while the company prepares for a Life Sciences Conference with Citizens to discuss Molbreevi's potential and launch preparations.
Citizens reiterated a Market Outperform rating and $10.00 price target for Savara (NASDAQ:SVRA) due to the likely FDA approval of Molbreevi for autoimmune pulmonary alveolar proteinosis (aPAP). The firm assigns a 90% probability of approval, citing a recent pulmonologist survey predicting strong uptake, and notes the stock has already seen a 106% return over the past year. Savara's management is set to attend Citizens' Life Sciences Conference to discuss the aPAP opportunity and launch preparations further.
Savara Inc. has amended its loan agreement with Hercules Capital, Inc., securing up to an additional $75 million, contingent on FDA approval of its rare lung disease drug, MOLBREEVI. This financing, combined with a previous royalty deal, brings Savara's potential non-dilutive capital to $150 million, providing strong financial backing for the drug's anticipated launch. MOLBREEVI, an investigational therapy for autoimmune pulmonary alveolar proteinosis, is awaiting a potential FDA approval in Q3 2026, with European filings also planned.
Savara has partnered with PANTHERx Rare for the exclusive distribution of its rare lung disease drug, molgramostim, in the U.S. if it receives FDA approval. The decision for molgramostim, intended for autoimmune pulmonary alveolar proteinosis (aPAP), is expected by June 28, 2024. This collaboration aims to ensure patient access to the first potential treatment for aPAP.
Savara, a clinical-stage biopharmaceutical company, has secured a non-dilutive royalty monetization agreement worth up to $75 million with HealthCare Royalty Partners. This deal provides funding to support the potential launch of MOLBREEVI (aeroVANC) for non-tuberculous mycobacteria (NTM) lung disease, pending successful Phase 3 clinical trials and regulatory approval. The initial $50 million upfront payment will strengthen Savara's balance sheet and extend its cash runway.